ORIGINAL ARTICLE

Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

Guosheng Yuan¹ | Xiaoyun Hu¹ | Qi Li¹ | Wencong Dai¹ | Xiao Cheng¹ | Pengfei Ying¹ | Wenxuan Yu¹ | Yabing Guo¹ | Mian Chen² | Jinzhang Chen¹

¹Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China

²Transplant Immunology Laboratory, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Headington, Oxford, UK

Correspondence

Jinzhang Chen, M.D., Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Ave, Guangzhou, Guangdong 510515, P.R. China.
Email: 13802522545@126.com

The above article from British Journal of Clinical Pharmacology, published online on July 5, 2020 in Wiley Online Library (<http://wileyonlinelibrary.com>) has been withdrawn by agreement among the authors and John Wiley & Sons Ltd on behalf of the British Pharmacology Society. The withdrawal has been agreed in accordance with the authors' decision to revise their study providing the latest data.